12.81
-0.49 (-3.68%)
| Previous Close | 13.30 |
| Open | 13.17 |
| Volume | 166,403 |
| Avg. Volume (3M) | 137,575 |
| Market Cap | 277,887,552 |
| Price / Book | 2.44 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -1.28 |
| Total Debt/Equity (MRQ) | 0.48% |
| Current Ratio (MRQ) | 25.86 |
| Operating Cash Flow (TTM) | -27.29 M |
| Levered Free Cash Flow (TTM) | -10.67 M |
| Return on Assets (TTM) | -15.91% |
| Return on Equity (TTM) | -34.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Aardvark Therapeutics, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.88 |
|
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 14.22% |
| % Held by Institutions | 49.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Laurion Capital Management Lp | 30 Jun 2025 | 989,068 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 212.26%) | Buy |
| Median | 25.00 (95.16%) | |
| Low | 19.00 (RBC Capital, 48.32%) | Buy |
| Average | 28.20 (120.14%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 11.92 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 01 Oct 2025 | 33.00 (157.61%) | Buy | 14.71 |
| Stifel | 29 Sep 2025 | 24.00 (87.35%) | Buy | 13.68 |
| HC Wainwright & Co. | 23 Sep 2025 | 40.00 (212.26%) | Buy | 11.44 |
| B of A Securities | 28 Aug 2025 | 25.00 (95.16%) | Buy | 8.49 |
| RBC Capital | 14 Aug 2025 | 19.00 (48.32%) | Buy | 11.26 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JONES BRYAN | - | - | 0 | 0 |
| LEE TIEN-LI | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JONES BRYAN | Officer | 15 Oct 2025 | Option execute | 1,250 | - | - |
| LEE TIEN-LI | Officer | 15 Oct 2025 | Option execute | 1,229 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |